1. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.
- Author
-
Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J, Wang F, Si W, Shu Y, Wei P, Fan G, Tian R, Wu H, Xu C, and Wang H
- Subjects
- Animals, Cell Line, Tumor, Down-Regulation, Female, Humans, Immunologic Memory immunology, Immunotherapy, Adoptive, Jurkat Cells, Male, Mice, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Mitochondria immunology, Neoplasms immunology, Neoplasms pathology, T-Lymphocytes cytology, Tumor Necrosis Factor Receptor Superfamily, Member 9 metabolism, Ubiquitination, Xenograft Model Antitumor Assays, Neoplasms therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology, T-Lymphocytes transplantation
- Abstract
Clinical evidence suggests that poor persistence of chimeric antigen receptor-T cells (CAR-T) in patients limits therapeutic efficacy. Here, we designed a CAR with recyclable capability to promote in vivo persistence and to sustain antitumor activity. We showed that the engagement of tumor antigens induced rapid ubiquitination of CARs, causing CAR downmodulation followed by lysosomal degradation. Blocking CAR ubiquitination by mutating all lysines in the CAR cytoplasmic domain (CAR
KR ) markedly repressed CAR downmodulation by inhibiting lysosomal degradation while enhancing recycling of internalized CARs back to the cell surface. Upon encountering tumor antigens, CARKR -T cells ameliorated the loss of surface CARs, which promoted their long-term killing capacity. Moreover, CARKR -T cells containing 4-1BB signaling domains displayed elevated endosomal 4-1BB signaling that enhanced oxidative phosphorylation and promoted memory T cell differentiation, leading to superior persistence in vivo. Collectively, our study provides a straightforward strategy to optimize CAR-T antitumor efficacy by redirecting CAR trafficking., Competing Interests: Declaration of Interests A patent application has been submitted based on results presented in this manuscript. H. Wang, P.W., W.L., and S.Q. are listed as the inventors. The authors declare no competing interests., (Copyright © 2020 Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF